VivoSeq
Oncology

Fallopian Tube Clear Cell Adenocarcinoma

10

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Fallopian Tube Clear Cell Adenocarcinoma is an early-stage landscape with 10 programs across 6 companies. The most active players are Teva, Avyxa, Johnson & Johnson. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 3A

Avyxa

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3AstraZeneca logo

AstraZeneca

2 programs

Phase 3G

Gynecologic Oncology Group

2 programs

Phase 3M

Meitheal

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Active, not recruiting3 · 100%

Clinical Trials

Trial Activity

Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Active, not recruiting·MMayo Clinic·Preclinical·NCT02068794·34 enrolled
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02446600·579 enrolled
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT02502266·582 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)